Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human leukocyte elastase (HLE), also known as neutrophil elastase, is a serine protease stored in neutrophils and released during inflammation. It degrades extracellular matrix proteins and cleaves plasma proteins, playing roles in neutrophil migration, phagocytosis, tissue remodeling, and pathogen destruction. Excessive HLE activity is implicated in diseases such as emphysema, cystic fibrosis, and rheumatoid arthritis, making it a therapeutic target. Natural and synthetic inhibitors can reduce its activity.
Serine protease inhibitors bind to the active site of human leukocyte elastase, preventing it from cleaving its target proteins.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Leukocyte Elastase (HLE).